A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, Shanghai, China
Contact: Study coordinator (Jianqing Mi, MD) · jianqingmi@shsmu.edu.cn · +86 13524488296

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Plasma Cell Leukemia

Abroad (travel likely)RecruitingEARLY_PHASE1

Shanghai, China

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma · Myelodysplastic Syndromes (MDS) · Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

Relapsed/Refractory Multiple Myeloma · Plasma Cell Leukemia (PCL)

Abroad (travel likely)RecruitingPHASE2

Changchun, China

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed/Refractory Multiple Myeloma

Abroad (travel likely)RecruitingPHASE1

Parkville, Australia